by John Conrad | Aug 5, 2024 | NewsBrief
COUR Pharmaceutical has been recognized as one of Fierce Biotech’s “Fierce 15” companies for 2024, joining an elite group of innovators shaping the future of the biotech industry. This annual list, curated by Fierce Biotech, highlights 15 companies...
by John Conrad | Aug 5, 2024 | NewsBrief
COUR Pharmaceuticals, a clinical-stage biotech company focused on developing treatments for autoimmune and inflammatory diseases, has announced a significant leadership transition. Founder John J. Puisis will step down as President and Chief Executive Officer, handing...
by John Conrad | Aug 2, 2024 | NewsBrief
On August 1, 2024, AbbVie completed its acquisition of Cerevel Therapeutics, marking a significant milestone in the quest to improve treatments for millions of people living with neurological and psychiatric conditions. This union brings together two companies...
by John Conrad | Aug 1, 2024 | NewsBrief
In a significant move to boost scientific innovation and commercialization, Portal Innovations is partnering with the University of Chicago’s Polsky Center for Entrepreneurship and Innovation to create a new science startup incubator. The collaboration will see...
by John Conrad | Aug 1, 2024 | NewsBrief
A team of researchers at the University of Illinois Urbana-Champaign (UIUC) has made a significant breakthrough in brain imaging technology that could revolutionize the diagnosis and treatment of Alzheimer’s disease. The study, published on July 31, 2024, in ACS...
by John Conrad | Jul 24, 2024 | NewsBrief
In a significant development for Illinois’ healthcare technology sector, Endotronix has been acquired by Edwards Lifesciences, a global leader in patient-focused innovations for structural heart disease and critical care monitoring. This acquisition marks a...
